Replies to post #198365 on Biotech Values

[biomaven0]

>>more financial based rather than science based

It's actually a very interesting blend of both - I'd tag them with the sui generis description.

Very leanly run with flat burn (wish other companies could follow that example) and steadily increasing revenues from their licensed products, with literally dozens of upcoming shots on goal from new products. Also have some very interesting projects of their own, one held internally but most spun out into another public company.

They had an analyst day a little while back - definitely worth a listen.

So looks like this transaction is an attempt to reproduce the Captisol acquisition. Lots of independent long-term shots on goal.

Peter

[biotech jim]

LGND, impressive deal to acquire OMT in my view.

I thought the captisol deal was great also.

Tremendous potential for LGND, but many of those programs remaining to licensed or progressed further in the clinic are the risk, due to their dormancy.

Long time holder for some reason.

[mcbio]

LGND -

Its one stock I sold WAY too early and regret since I sold to raise cash thinking it was ahead of itself.

Same with me. Was chatting with someone tonight and it caused me to re-think LGND. Seems like nearest big potential value driver could be if MRK P3 for MK-8931 (BACE inhibitor to which LGND is due undisclosed royalties) shows any positive hint of efficacy. The person I was chatting with mentioned that no other AD drug has advanced to P3 to date having shown the ability to lower soluble forms of amyloid beta in the clinic (as apparently MK-8931 has). Anyone have any comments on likelihood this will differentiate MK-8931 from the litany of prior AD drugs targeting amyloid beta that have failed in the clinic?